- 2 years ago
BMS says 'no go' to its latest PBAC recommendation (istock.com/Dilok Klaisataporn)
3 November 2021 BMS has pulled its blockbuster immuno-oncology drug OPDIVO (nivolumab) from post-PBAC pricing…
This is subscriber-only content. Please login to continue reading.